This is a phase IV clinical study to demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing restful sensation to the eyes. This will be evaluated by measuring the incidence of unexpected adverse events related to the interventions, the incidence of conjunctival hyperemia and the incidence of sensation of comfort with the application, when applied by the Principal Investigator (PI).

Start Date30 Jun 2024

Sponsor / Collaborator

Laboratorios Sophia SA de CV

NCT05999630 / RecruitingPhase 3IIT

The Use of Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Who Are Treated With Radioactive Iodine for Thyroid Cancer

The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.

Start Date21 Aug 2023

Sponsor / Collaborator

Vanderbilt University Medical Center

CTRI/2023/04/051788 / Not yet recruitingPhase 3IIT

COMPARATIVE STUDY OF PAIN PERCEPTION ASSESSMENT USING VISUAL ANALOGUE SCALE IN PATIENTS UNDERGOING CATARACT SURGERY BY PHACOEMULSIFICATION UNDER TOPICAL ANESTHESIA- WITH AND WITHOUT USE OF LUBRICATION BETWEEN TWO TYPES OF EYELID SPECULUMS

Start Date21 Apr 2023

Sponsor / Collaborator-

100 Clinical Results associated with Hypromellose

100 Translational Medicine associated with Hypromellose

100 Patents (Medical) associated with Hypromellose

2,786

Literatures (Medical) associated with Hypromellose

01 Mar 2024·Journal of the mechanical behavior of biomedical materials

Remineralizing effects of hydroxypropyl methylcellulose film-loaded amorphous calcium phosphate nanoprecursors on enamel artificial caries lesions

Article

Author: Zheng, Haiyan ; Cui, Zihan ; Wu, Zhifang ; Zhou, Zihuai ; Fu, Baiping ; Zhang, Zhixin ; Zhang, Jianping ; Wang, Zhe

OBJECTIVES:

This study was to investigate hydroxypropyl methylcellulose (HPMC) film as a carrier for amorphous fluorinated calcium phosphate (AFCP) nanoprecursors to continuously deliver biomimetic remineralization of enamel artificial caries lesions (ACL).

MATERIALS AND METHODS:

The AFCP/HPMC films were comprised of 25 wt% AFCP nanoparticles and 75 wt% HPMC. They were characterized by transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), and biocompatibility tests. Forty enamel ACL were prepared and randomly divided into four groups (n = 10): The enamel surfaces were covered with a pure HPMC film, Tooth Mousse Plus (contains 10% CPP-ACP and 0.2% NaF), and AFCP/HPMC film, or without any things (serving as negative control). Subsequently, all samples were alternatively kept in artificial saliva and a modified pH-cycling before they were characterized by Micro-CT, scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX), attenuated total reflectance (ATR)-FTIR, XRD, and nanoindentation.

RESULTS:

After the enamel ACL was challenged by pH cycling, Tooth Mousse Plus and AFCP/HPMC film groups exhibited less lesion depth and mineral loss than the negative control and pure HPMC film groups. Additionally, the AFCP/HPMC film group revealed a highest remineralization rate of 55.34 ± 3.10 % among the all groups (p < 0.001). The SEM findings showed that the enamel ACL were densely deposited with minerals in the AFCP/HPMC film group, and the EDX results suggested a higher content of fluorine in the remineralized tissues. In particular, the AFCP/HPMC film group exhibited the best nanomechanical performance after 2 weeks of pH cycling (p < 0.05), with the hardness (H) restored from 0.29 ± 0.19 to 2.69 ± 0.70 GPa, and elastic modulus (Er) restored from 10.77 ± 5.30 to 68.83 ± 12.72 GPa.

CONCLUSION:

The AFCP/HPMC film might be used as a promising strategy for arresting or reversing incipient enamel caries lesions.

01 Mar 2024·International journal of biological macromolecules

Zein and hydroxypropyl methylcellulose acetate succinate microfibers combined with metronidazole benzoate and/or metronidazole-incorporated cellulose nanofibrils for potential periodontal treatment

Article

Author: Zambuzi, Giovana C ; Camargos, Camilla H M ; Ferreira, João O ; de Freitas, Osvaldo ; Carvalho, Ana C W ; Francisco, Kelly R ; Ferreira, Maíra P ; Rezende, Camila A

The development of flexible and porous materials to control antibacterial delivery is a pivotal endeavor in medical science. In this study, we aimed to produce long and defect-free fibers made of zein and hydroxypropyl methylcellulose acetate succinate (HPMCAS) to be used as a platform for the release of metronidazole (MDZ) and metronidazole benzoate (BMDZ) to be potentially used in periodontal treatment. Microfibers prepared via electrospinning under a 2:3 (w/w) zein to HPMCAS ratio, containing 0.5 % (w/w) poly(ethylene oxide) (PEO) and 1 % (w/w) cellulose nanofibril (CNF) were loaded with 40 % (w/w) MDZ, 40 % (w/w) BMDZ, or a combination of 20 % (w/w) of each drug. The addition of CNF improved the electrospinning process, resulting in long fibers with reduced MDZ and BMDZ surface crystallization. MDZ- and BMDZ-incorporated fibers were semicrystalline and displayed commendable compatibility among drugs, nanocellulose and polymeric chains. Release tests showed that zein/HPMCAS/PEO fibers without CNF and with 20 % (w/w) MDZ/ 20 % (w/w) BMDZ released the drug at a slower and more sustained rate compared to other samples over extended periods (up to 5 days), which is a favorable aspect concerning periodontitis treatment.

01 Mar 2024·Drug delivery and translational research

Guar gum as a microbially degradable component for an oral colon delivery system based on a combination strategy: formulation and in vitro evaluation

Article

Author: Moutaharrik, Saliha ; Caloni, Francesca ; Meroni, Gabriele ; Foppoli, Anastasia ; Cerea, Matteo ; Maroni, Alessandra ; Gazzaniga, Andrea ; Palugan, Luca ; Martino, Piera Anna ; Soggiu, Alessio

Oral colon delivery has widely been pursued exploiting naturally occurring polysaccharides degraded by the resident microbiota. However, their hydrophilicity may hinder the targeting performance. The aim of the present study was to manufacture and evaluate a double-coated delivery system leveraging intestinal microbiota, pH, and transit time for reliable colonic release. This system comprised a tablet core, a hydroxypropyl methylcellulose (HPMC) inner layer and an outer coating based on Eudragit^® S and guar gum. The tablets were loaded with paracetamol, selected as a tracer drug because of the well-known analytical profile and lack of major effects on bacterial viability. The HPMC and Eudragit^® S layers were applied by film-coating. Tested for in vitro release, the double-coated systems showed gastroresistance in 0.1 N HCl followed by lag phases of consistent duration in phosphate buffer pH 7.4, imparted by the HPMC layer and synergistically extended by the Eudragit^® S/guar gum one. In simulated colonic fluid with fecal bacteria from an inflammatory bowel disease patient, release was faster than in the presence of β-mannanase and in control culture medium. The bacteria-containing fluid was obtained by an experimental procedure making multiple tests possible from a single sampling and processing run. Thus, the study conducted proved the feasibility of the delivery system and ability of guar gum to trigger release in the presence of colon bacteria without impairing the barrier properties of the coating. Finally, it allowed an advantageous simulated colonic fluid preparation procedure to be set up, reducing the time, costs, and complexity of testing and enhancing replicability.

News (Medical) associated with Hypromellose

29 May 2024

·www.sciencedaily.com

Could a medicated foam make gene therapies more accessible?

Bioengineers report that a foaming liquid worked better than a standard liquid formulation at transferring gene therapy components to cells in laboratory studies. Foam mixed with medications is already used to treat conditions such as varicose veins, hemorrhoids, wounds on the skin and even hair loss. Now, Fred Hutch Cancer Center scientists have found that foam might also be used as a vehicle to deliver expensive gene therapies. Published May 28 in Nature Communications, bioengineer Matthias Stephan, MD, PhD, and his Fred Hutch team report that a foaming liquid worked better than a standard liquid formulation at transferring gene therapy components to cells in laboratory studies. "Gene therapies are the new wave of medicine, but they are extremely expensive and difficult to make," said Stephan, a professor in the Translational and Therapeutics Division at Fred Hutch. "Our gene therapy foam shows for the first time that by taking a small amount of an expensive gene therapy drug, increasing its volume by embedding it in a solution that is mostly made of densely packed air bubbles and then applying it to cells, we can achieve a strong and safe transfer of gene therapy agents to cells." Gene therapies in development for cancers, infectious diseases, inherited disorders and other diseases hold tremendous promise for providing long-lasting treatments by fixing the underlying biology. However, they also face major barriers including getting the therapies to the parts of the body where they're needed and the high cost of making laboratory-modified viruses called vectors that deliver therapies to diseased cells. Foam could be the key to delivering gene therapies more simply and cheaply. While the study is proof-of-concept, Stephan envisions the gene therapy foam as a possible solution for treating cancers that are in confined spaces, such as ovarian, pancreatic and gastrointestinal cancer and autoimmune diseases that affect the digestive system. "The foam could be applied to confined spaces to push again body tissues that have the disease, and the medication in the foam could adhere to those diseased cells," Stephan explained. "Then as the air bubbles pop, the liquid with the gene therapy can drain away." Stephan has used other materials, such as nanoparticles and a tiny implantable sponge, to deliver genetic instructions to fight disease directly to cells. Looking for a new delivery vehicle, he was inspired by shaving foam. "Foam is mostly gas bubbles separated by thin liquid films and it is already safely used in medicines and the food industry," Stephan said. "We have not seen foam used with genetic materials, and I wondered if it could help solve the problem of gene therapy delivery." In the lab In a series of lab experiments, Stephan and his team examined whether they could take a small amount of very expensive gene therapy vectors, mix them with gene editing materials and different foaming agents, and then apply the mixture to cells to see if the cells would take up the gene edits. To test their approach, the team used another immune-based therapy: the mRNA for a COVID-19 vaccine, which teaches the immune system to attack the virus by showing the immune system the biological code for what the virus looks like. The Fred Hutch team made their own solution of a COVID-19 mRNA vaccine with a biological tweak that allowed it to glow once it was delivered to cells. This way, once the lab-engineered gene therapy product was taken up by cells, the team could see it using a microscope. To develop the foam, the team determined methylcellulose, a food additive used in ice cream and other products, created the best foam for transferring gene therapy product to cells and stayed in place where it was deposited. When the team mixed the foam with cells, the foam substantially boosted gene transfer and outperformed liquid formulations. Then, when the team injected a small amount of foam into the abdominal cavity of mice, within one day the gene therapy transferred from the foam to the targeted cells without significant side effects. Beyond the lab The technology is many years from being used in people. Stephan hopes to attract external academic and industry collaborators to further develop the approach. "The goal of my work is to make modern medicines work better for people everywhere," Stephan said. "I believe that our future medical breakthroughs will arise from our deep understanding of disease biology and our knack for finding innovative solutions in unexpected places."

VaccineGene TherapymRNA

20 Jul 2023

·www.prnewswire.com

REXULTI (brexpiprazole): Approved as Adjunctive Therapy to Treat Adults with MDD and Schizophrenia - Drug Insights and Market Forecasts to 2032 - Focus on 7 Major Markets

DUBLIN, July 20, 2023 /PRNewswire/ -- The "REXULTI Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "This "REXULTI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REXULTI for schizophrenia in the seven major markets. A detailed picture of the REXULTI for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the REXULTI for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REXULTI market forecast analysis for schizophrenia in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia. Drug Summary REXULTI (brexpiprazole) is approved as adjunctive therapy to treat adults with major depressive disorder (MDD) and schizophrenia. It is also approved to be used as adjunctive therapy to antidepressants for MDD treatment). REXULTI was discovered by Otsuka and co-developed with Lundbeck. It is co-marketed by two companies and became available to patients in the US in August 2015. The inactive ingredients consist of lactulose monohydrate, cornstarch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, and colorants of titanium dioxide, iron oxide, and ferrous ferric oxide. Also, brexpiprazole is a round tablet with six strengths ranging from 0.25 mg to 4 mg. Dosage and Administration The recommended starting dosage for REXULTI is 1 mg once daily on Days 1-4, orally with or without food. The recommended target REXULTI dosage is 2-4 mg once daily. The drug is titrated to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg. Mechanism of Action The mechanism of action of brexpiprazole in the treatment of MDD or schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors and antagonist activity at serotonin 5-HT2A receptors. In-depth REXULTI Market Assessment This report provides a detailed market assessment of REXULTI for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032. REXULTI Clinical Assessment The report provides the clinical trials information of REXULTI for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates. Scope of the Report A comprehensive product overview including the REXULTI description, mechanism of action, dosage and administration, research and development activities in schizophrenia. Elaborated details on REXULTI regulatory milestones and other development activities have been provided in this report. The report also highlights the REXULTI research and development activities in schizophrenia across the United States, Europe and Japan. The report also covers the patents information with expiry timeline around REXULTI. The report contains forecasted sales of for schizophrenia till 2032. Comprehensive coverage of the late-stage emerging therapies for schizophrenia. The report also features the SWOT analysis with analyst views for REXULTI in schizophrenia. Report Highlights In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REXULTI dominance. Other emerging products for schizophrenia are expected to give tough market competition to REXULTI and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REXULTI in schizophrenia. The in-depth analysis of the forecasted sales data of REXULTI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REXULTI in schizophrenia. Key Topics Covered: 1. Report Introduction 2. REXULTI Overview in Schizophrenia 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and Efficacy 2.3. Regulatory Milestones 2.4. Other Developmental Activities 2.5. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. REXULTI Market Assessment 5.1. Market Outlook of REXULTI in Schizophrenia 5.2. 7MM Analysis 5.2.1. Market Size of REXULTI in the 7MM for Schizophrenia 5.3. Country-wise Market Analysis 5.3.1. Market Size of REXULTI in the United States for Schizophrenia 5.3.2. Market Size of REXULTI in Germany for Schizophrenia 5.3.3. Market Size of REXULTI in France for Schizophrenia 5.3.4. Market Size of REXULTI in Italy for Schizophrenia 5.3.5. Market Size of REXULTI in Spain for Schizophrenia 5.3.6. Market Size of REXULTI in the United Kingdom for Schizophrenia 5.3.7. Market Size of REXULTI in Japan for Schizophrenia 6. SWOT Analysis 7. Analysts' Views 8. Appendix For more information about this drug pipelines report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Drug ApprovalClinical Result

14 Feb 2023

·www.biospace.com

Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing

House dust mite study shows statistically significant reduction in symptoms vs. no protection Grass pollen study shows faster onset of action and superior efficacy ratings by patients Bentrio® shows wider nasal cavity distribution, for 3.5 x more time, vs saline spray HAMILTON, BERMUDA / ACCESSWIRE / February 14, 2023 / Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Antonio, TX. Presentation Details Session Date & Time: Saturday, February 25, 2023, 10:45 am - 11:45 am ET Poster No. 337: Efficacy and Tolerability of the Barrier-Forming Drug-Free Nasal Spray AM-301 in Allergic Rhinitis Patients Exposed to Controlled Grass Pollen and House Dust Mite Challenge Presenting Author: Anne Marie Salapatek, Ph.D., Cliantha Research, Mississauga, Ontario, Canada The presentation will include data from the following clinical evaluations: House dust mite (HDM) allergic rhinitis. The randomized cross-over study in 37 patients undergoing controlled allergen exposure for 3 hours showed a statistically significant reduction in the change of the Total Nasal Symptom Score (TNSS) with application of Bentrio compared to no protection (publication submitted). The study was conducted by Cliantha Research, Canada. Grass pollen allergic rhinitis. The randomized cross-over study in 36 patients undergoing controlled allergen exposure for 4 hours showed: non-inferiority with regard to the change in the TNSS for Bentrio compared to a hydroxypropyl methylcellulose nasal spray, faster onset of protection, and better subjective ratings of efficacy[1]. The study was conducted by the Fraunhofer Institute for Toxicology and Experimental Medicine, Germany. Nasal residence time. The randomized study in 8 healthy volunteers showed wide distribution of fluorescence-labelled Bentrio for 3.5 hours within relevant parts of the nasal cavity compared to smaller coverage and presence for only one hour with labelled saline nasal spray (publication submitted). The study was conducted by the University of Tubingen, Germany. All three studies of Bentrio nasal spray demonstrated good safety and tolerability. About The 2023 AAAAI Annual Meeting The 2023 AAAAI Annual Meeting will take place February 24-27 in San Antonio, TX. The conference draws academic and clinical leaders from around the world to showcase new research and discuss other developments in allergy, asthma and immunologic diseases. For more info, visit: About Altamira Therapeutics Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore™ / SemaPhore™ delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The versatile delivery platform is also suited for mRNA and other types of RNA therapeutics and shall be leveraged via out-licensing to pharma or biotech companies. In addition, Altamira is in the process of divesting and/or licensing-out its legacy assets in allergology and viral infection (Bentrio® OTC nasal spray; commercial) and inner ear therapeutics (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: Forward-Looking Statements This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of the continued commercialization of Bentrio and success of strategic transactions, including licensing or partnering, with respect to Bentrio or any other legacy assets, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: . Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. CONTACT Hear@altamiratherapeutics.com 800-460-0183 SOURCE: Altamira Therapeutics View source version on accesswire.com:

Clinical ResultPhase 2Phase 3

100 Deals associated with Hypromellose

External Link

KEGG	Wiki	ATC	Drug Bank
D04481	Hypromellose	S01KA02	DB11075

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Pain	CN	Alcon-Couvreur NV	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Phase 2	CN	Lee's Pharmaceutical Holdings Ltd.	09 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01812044 (CTgov)	Not Applicable	Strabismus \| Pain, Postoperative	57	topical control - 0.5 cc of Hypromellose 0.3% gel+subtenons anesthetic - preservative-free bupivacaine 0.75% (Subtenons Anesthetic and Topical Control)	ljekupxtqc(ttmneqvbhj) = nwrmhwddua jidkrhfpnt (ljdyuzmedw, sijhmvemzf - przmrsygph) View more	-	26 Apr 2016
				subtenons control - 0.5 cc of Normal Saline+topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel (Topical Anesthetic and Subtenons Control)	ljekupxtqc(ttmneqvbhj) = qcmwnqzkgt jidkrhfpnt (ljdyuzmedw, ihuycgsqyp - apznbkvzsg) View more
NCT00598689 (CTgov)	Phase 4	Corneal epithelial defect	80	0.3% hypromellose (Lubricant)	hcrhgcqbvj(nqsoztjitn) = lesxenernf pvvxdxpjcs (vbvstchyuz, yvizcdgbiv - ibrceggqlt) View more	-	07 Mar 2016
				hypromellose (No Lubricant)	hcrhgcqbvj(nqsoztjitn) = fgouarunqr pvvxdxpjcs (vbvstchyuz, dzlqcdixul - aunkvbafrv) View more
NCT02097719 (CTgov)	Phase 4	Glaucoma	100	hypromellose 0.3%+bimatoprost 0.01% (Bimatoprost 0.01% and Hypromellose 0.3%)	zevzogwrul(lizsktgqqd) = euhuxtjghe yaxkvsmrct (zaebjeguda, qumqwgwyca - ofuyjlowzi) View more	-	14 Jan 2016
				timolol 0.5%+travoprost 0.004% (Travoprost 0.004% and Timolol 0.5%)	zevzogwrul(lizsktgqqd) = abltwagujw yaxkvsmrct (zaebjeguda, ezjnrrepvx - nvbzsyvejr) View more
NCT01881126 (CTgov)	Phase 4	Glaucoma	93	hypromellose 0.3%+bimatoprost 0.01% (Bimatoprost 0.01% and Hypromellose 0.3%)	xfwbkprilc(tsrczlbaul) = abkleiinyg vwmjjlfboa (rtoghbnggb, bdjbybcvtd - gdzutonmpd) View more	-	30 Nov 2015
				timolol 0.5%+travatan 0.004% (Travatan 0.004% and Timolol 0.5%)	xfwbkprilc(tsrczlbaul) = fcilicfowd vwmjjlfboa (rtoghbnggb, dfbngkfvfq - wnefxyiesu) View more
NCT01525173 (CTgov)	Phase 4	Glaucoma	137	0.01% bimatoprost ophthalmic solution+latanoprost 0.005% ophthalmic solution+0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P and LUMIGAN®)	hudqpyxabf(hoxqozfiyt) = gkpaayxgbg gvdhcsgrpa (zvacunejhf, sinlrnxtcq - vxjfgucopc) View more	-	04 Dec 2013
				0.2% hypromellose lubricant eye drops+0.01% bimatoprost ophthalmic solution+latanoprost 0.005% ophthalmic solution (LUMIGAN® Alone)	hudqpyxabf(hoxqozfiyt) = hsgiwlzhwe gvdhcsgrpa (zvacunejhf, vahabkpmky - nwgluaomwr) View more
NCT01280110 (CTgov)	Phase 4	Dry Eye Syndromes	44	Hydroxypropylmethylcellulose (Preserved (BAK 0.006%) Lubricating Drop)	bhsbukxror(xkfgfapcfu) = kzckfyniqq qelzymhcdc (qifkegpofq, ckyvopkmlv - meitcdhjdx) View more	-	12 Jul 2012
				Carboxymethylcellulose (Preservative-free Lubricating Drops)	bhsbukxror(xkfgfapcfu) = lwylmydtsw qelzymhcdc (qifkegpofq, tuphbtqnhf - rwwsjrvnaz) View more
NCT00909324 (CTgov)	Phase 4	Dry Eye Syndromes	170	Pre-LASIK 0.3% hypromellose (Pre-LASIK 0.3% Hypromellose)	eqckiyyrnd(zazpsucfqu) = nnebkwxyhu nxpomdgbqr (wbtznkgdhi, bwgwylljsx - vswgoupukc) View more	-	24 Mar 2011
				Post-LASIK 0.3% hypromellose (Post-LASIK 0.3% Hypromellose)	eqckiyyrnd(zazpsucfqu) = esvzrpvmlx nxpomdgbqr (wbtznkgdhi, tmwwmjwequ - ugwevmbhun) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hypromellose

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation